Guidelines: Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis in HIV-Infected Patients Taking Protease Inhibitors or Non-nucleoside Reverse Transcriptase Inhibitors

  • Centers for Disease Control and Prevention National Center for HIV, STD and TB Prevention, Division of Tuberculosis Elimination


Two previously published reports provided guidelines for managing the pharmacological interactions that can result when patients are treated with protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) for human immunodeficiency virus (HIV) infection together with rifamycins for tuberculosis (TB).1,2 This article presents current data pertaining to interactions between these agents, with recommendations for their use from a group of Centers for Disease Control (CDC) scientists and outside expert consultants; these include initial recommendations for the PIs lopinavir/ritonavir, atazanavir, and fosamprenavir (a phosphate ester prodrug of amprenavir)
Southern African Journal of HIV Medicine Vol. 5 (1) 2004: 28-32

Journal Identifiers

eISSN: 2078-6751
print ISSN: 1608-9693